onvuzosiran   Click here for help

GtoPdb Ligand ID: 14731

Synonyms: ADX-324 | ADX324
Compound class: Nucleic acid
Comment: Onvuzosiran (ADX-324) is a GalNAc-conjugated small interfering RNA (siRNA) that is proposed to reduce prekallikrein (PKK) expression at the mRNA level. GalNAc conjugation is used to promote targeted hepatic delivery. in the nucleotide sequences provided here (reproduced from the INN record) the GalNAc sugar is attached at the R1 position. The nucleotides are chemically modified (2'-O-methylnucleotides/2'-MOE and 2'-deoxy-2'-fluoronucleotide/2'-F monomers), with a mixed phosphorothioate/phosphate backbone, to improve RNA binding and pharmacokinetics.
No information available.
Summary of Clinical Use Click here for help
Onvuzosiran (ADX-324) was progressed as a clinical candidate to evaluate it as a potential treatment for hereditary angioedema (HAE) [1].
Clinical Trials
Clinical Trial ID Title Type Source Comment References
NCT07428499 Phase 3 Extension Study of ADX-324 in Participants With Hereditary Angioedema (HAE) Phase 3 Interventional ADARx Pharmaceuticals, Inc.
NCT06960213 STOP-HAE: A Phase 3 Study of ADX-324 in HAE Phase 3 Interventional ADARx Pharmaceuticals, Inc.
NCT05691361 Safety, Tolerability, PK, PD of ADX-324 in Healthy Volunteers and Hereditary Angioedema Patients Phase 1/Phase 2 Interventional ADARx Pharmaceuticals, Inc.